TopFunds

Insulet Corporation

NASDAQ: PODD

Stock price

150.79 USD

(+0%) TODAY

Health Care EquipmentMedical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(1.3)
(0.5)
(0.5)
0.1
0.2
0.1
0.3
0.1
2.9
5.8
3.5
-
02Free cash flow per share
(0.4)
(0.1)
(0.6)
(2.1)
(1.2)
(1.3)
(2.8)
(0.5)
1
4.1
5.3
-
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
$ 263.9
$ 367
$ 463.8
$ 563.8
$ 738.2
$ 904.4
$ 1,099
$ 1,305
$ 1,697
$ 2,072
$ 2,708
26.2%
06% Change
-
39.1%
26.4%
21.6%
30.9%
22.5%
21.5%
18.8%
30%
22.1%
30.7%
26.2%
07Cost of revenue
(130.6)
(155.9)
(186.6)
(193.7)
(257.9)
(322.1)
(346.7)
(499.7)
(537.2)
(625.9)
(768.2)
19.4%
08Gross profit
133.3
211.1
277.2
370.2
480.3
582.3
752.1
805.6
1,160
1,446
1,940
30.7%
09% Margin
50.5%
57.5%
59.8%
65.7%
65.1%
64.4%
68.5%
61.7%
68.4%
69.8%
71.6%
63.9% A
10Operating expenses
(182)
(221.8)
(284.6)
(342.8)
(430.3)
(530.8)
(626.1)
(768)
(939.9)
(1,137)
(1,466)
23.2%
11% of Revenue
(69)%
(60.4)%
(61.4)%
(60.8)%
(58.3)%
(58.7)%
(57)%
(58.8)%
(55.4)%
(54.9)%
(54.1)%
(59)% A
12Operating Income
(48.7)
(10.7)
(7.4)
27.4
50
51.5
126
37.6
220
308.9
473.8
-
13Income tax expense
(0.2)
(0.4)
(0.2)
(1.9)
(2.9)
(2.9)
(3.7)
(5.2)
(8.3)
(118.1)
(92.4)
83.6%
14Net Income
(73.5)
(28.9)
(26.8)
3.3
11.6
6.8
16.8
4.6
206.3
418.3
247.1
-
15% Margin
(27.9)%
(7.9)%
(5.8)%
0.6%
1.6%
0.8%
1.5%
0.4%
12.2%
20.2%
9.1%
0.4% A
16Shares Outstanding
56,786
57,251
58,003
61,008
62,304
65,946
68,579
69,910
73,633
73,890
71,886
2.4%
17EPS Basic
(1.3)
(0.5)
(0.5)
0.1
0.2
0.1
0.3
0.1
3
6
3.5
-
18EPS Diluted
(1.3)
(0.5)
(0.5)
0.1
0.2
0.1
0.3
0.1
2.9
5.8
3.5
-
19EBITDA
(32.8)
1.4
6.4
47.1
74.2
110.3
139.6
109
323.6
423.7
509.6
-
% Margin
(12.4)%
0.4%
1.4%
8.4%
10.1%
12.2%
12.7%
8.4%
19.1%
20.5%
18.8%
9% A
20Net Interest Income (expense)
(12.7)
(13.6)
(16.6)
(15.5)
(34.6)
(45.1)
(61.2)
(26.7)
(7.6)
(3.2)
(45)
13.5%
21Net Debt / EBITDA
(1.7)
139.6
45.9
10.2
9.5
1.5
3.5
7.4
2.5
1.1
0.7
20 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
122.7
137.2
272.6
113.9
203.7
907.2
791.6
623.9
650.7
953.4
716.1
19.3%
23Short-term investments
-
161.4
167.5
175
172.4
40.4
-
50.8
53.5
-
-
-
24Accounts receivable
42.5
28.8
53.4
76.7
82.8
83.8
161
205.6
359.7
365.5
516.9
28.4%
25Other current assets
13.5
7.1
9.9
17
21.6
52
60.7
71.7
99.8
121.9
203.1
31.1%
26Inventory
12
35.5
33.8
71.4
101
154.3
303.2
346.8
402.6
430.4
452.6
43.7%
27Total Current Assets
190.8
370
537.2
454
581.5
1,238
1,317
1,299
1,566
1,871
1,889
25.8%
Non-Current Assets
28Net property, plant & equipment
41.8
46.3
107.9
258.4
415.5
493.6
546.4
625.9
692.8
759.8
863.2
35.4%
29Long-term investments
-
-
125.5
140.8
58.4
14.8
19.3
15
-
5.5
20.1
-
30Other non-current assets
42.6
40.4
46.2
75.6
87.5
126.8
166.6
311.4
329.1
451.2
418.4
25.7%
31Total Non-Current Assets
84.4
86.7
279.6
474.7
561.4
635.2
732.3
952.3
1,022
1,217
1,302
31.5%
Total Assets
275.1
456.6
816.7
928.7
1,143
1,873
2,049
2,251
2,588
3,088
3,190
27.8%
LIABILITIES
Current Liabilities
32Accounts payable
15.2
13.2
24.4
25.5
54.5
54.1
37.7
30.8
19.2
19.8
75
17.3%
33Short-term debt
5.5
0.3
-
-
3.6
20.5
30.1
31.1
52.9
85.9
22.2
14.9%
34Other current liabilities
44.4
42.3
61.6
90.2
99.6
133.2
161
302.8
379.1
422.7
582.9
29.4%
35Total Current Liabilities
65.2
55.7
86
115.7
157.7
207.8
228.8
364.7
451.2
528.4
680.1
26.4%
Non-Current Liabilities
36Long-term debt
172.2
332.8
566.2
592
902.3
1,056
1,256
1,402
1,396
1,336
1,029
19.6%
37Other non-current liabilities
3.7
5
6
9
7
5.8
7.3
8.3
8.4
11.6
(33.5)
-
38Total Non-Current Liabilities
175.9
337.8
572.2
601
909.3
1,062
1,264
1,410
1,404
1,348
995.1
18.9%
39Total Liabilities
241.1
393.5
658.2
716.6
1,067
1,269
1,493
1,775
1,856
1,876
1,675
21.4%
SHAREHOLDERS` EQUITY
40Common stock
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
5.8%
41Retained earnings / (deficit)
(651.5)
(680.4)
(707.3)
(683.6)
(672)
(666.3)
(649.5)
(584.3)
(378)
40.3
287.4
-
42Accumulated other comprehensive income / (loss)
(0.7)
(0.7)
(0.5)
(2.9)
(1.2)
5.5
(2.2)
20
8
(13.2)
13.2
-
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
34.1
63.2
158.5
212.1
75.9
603.6
556.3
476.4
732.7
1,212
1,515
46.2%
45Total Liabilities and shareholders' Equity
275.1
456.6
816.7
928.7
1,143
1,873
2,049
2,251
2,588
3,088
3,190
27.8%
46Total Debt
177.5
333
566.2
592
905.9
1,076
1,287
1,433
1,449
1,422
1,051
19.5%
47Net Debt
54.8
195.9
293.6
478.1
702.2
169
494.9
808.9
798.1
468.6
334.7
19.8%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(73.5)
(28.9)
(26.8)
3.3
11.6
6.8
16.8
4.6
206.3
418.3
247.1
-
49Depreciation & amortization
15.8
13.8
13.9
15.6
27.9
55.4
57.4
63.2
72.8
80.8
90.4
19%
50Share-based compensation expense
19.2
23.6
31.9
37.5
28.7
35.9
34.4
40.9
48.3
69.3
62.7
12.6%
51Changes in working capital and other assets
26
7.3
22.3
(20.5)
30.2
(14.1)
(176.7)
10.3
(181.7)
(138.1)
169.1
20.6%
52Net cash flows from operating activities
(12.6)
15.9
41.3
35.9
98.4
84
(68.1)
119
145.7
430.3
569.3
-
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(10.6)
(22.1)
(77.2)
(162.4)
-
(166.5)
(122.7)
(157.3)
(109.2)
(134)
(191.6)
33.6%
54Purchases of investments / marketable securities
-
(177.7)
(298)
(191.4)
(150.6)
(37.9)
-
(7.8)
(7.2)
(12.2)
-
-
55Proceeds from maturities of marketable securities
-
16
164.4
169.3
247.9
218.4
40
-
-
-
-
-
56Other investing activities
(4.7)
5.7
-
-
(170.9)
-
-
(26)
(3)
-
(31.1)
20.8%
57Net cash flows from investing activities
(15.3)
(178)
(210.8)
(184.5)
(73.6)
14
(82.7)
(191.1)
(119.4)
(146.2)
(222.7)
30.7%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
7.9
4.9
15.8
15.8
(34.5)
509.2
23.5
16.3
26.9
20.1
(25.7)
-
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
(5.6)
174.6
292.8
(6.7)
116.6
126.6
49.4
(39.8)
(27)
(40.6)
(708.1)
62.3%
61Other financing activities
(2.6)
(2.9)
(4.1)
(17.8)
(8.6)
(30.3)
(32.2)
(16.8)
(13.5)
(7.6)
138.5
-
62Net cash flows from financing activities
(0.4)
176.6
304.5
(8.7)
73.5
605.5
40.7
(40.3)
(13.6)
(28.1)
(595.3)
109.2%
63Increase (decrease) in cash and cash equivalents
(28.5)
14.5
135.4
(158.7)
99.8
708.3
(115.6)
(116.7)
14.5
249.2
(237.3)
23.6%
64Cash and equivalents, ending balance
122.7
137.2
272.6
113.9
213.7
922
806.4
689.7
704.2
953.4
716.1
19.3%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
(23.2)
(6.2)
(35.9)
(126.5)
98.4
(82.5)
(190.8)
(38.3)
36.5
296.3
377.7
-

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Insulet Corporation (PODD) financial statements and performance

Explore Insulet Corporation (PODD) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.